Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients

Eur J Intern Med. 2023 Jun:112:118-120. doi: 10.1016/j.ejim.2023.01.024. Epub 2023 Feb 6.
No abstract available

Keywords: Acute respiratory distress syndrome; Anakinra; COVID-19; Mortality; Tocilizumab.

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Models, Statistical
  • Pneumonia* / drug therapy
  • Treatment Outcome

Substances

  • Interleukin 1 Receptor Antagonist Protein
  • tocilizumab